Maguire, Albert M <br/><br/>
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.  [electronic resource] 

 -  Lancet (London, England)  Nov 2009 
 - 1597-605 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(09)61836-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Age Factors<br/>Blindness--congenital<br/>Carrier Proteins--genetics<br/>Child<br/>Dark Adaptation<br/>Dependovirus--genetics<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Electroretinography<br/>Eye Proteins--genetics<br/>Female<br/>Genetic Therapy--methods<br/>Genetic Vectors--genetics<br/>Humans<br/>Injections<br/>Male<br/>Mutation--genetics<br/>Nystagmus, Physiologic<br/>Optic Atrophy, Hereditary, Leber--diagnosis<br/>Safety<br/>Treatment Outcome<br/>Visual Acuity<br/>Young Adult<br/>cis-trans-Isomerases